MX2022013304A - Formas cristalinas de compuesto de ftalazinona. - Google Patents

Formas cristalinas de compuesto de ftalazinona.

Info

Publication number
MX2022013304A
MX2022013304A MX2022013304A MX2022013304A MX2022013304A MX 2022013304 A MX2022013304 A MX 2022013304A MX 2022013304 A MX2022013304 A MX 2022013304A MX 2022013304 A MX2022013304 A MX 2022013304A MX 2022013304 A MX2022013304 A MX 2022013304A
Authority
MX
Mexico
Prior art keywords
crystalline forms
compound
same
phthalazin
cyclopropylamino
Prior art date
Application number
MX2022013304A
Other languages
English (en)
Inventor
Kunhee Lee
Seoktaek Lee
Keuncheol Ryu
Hanna Seo
Hyeran Yang
Wonje Seong
Jinyoung Yoon
Original Assignee
Idience Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idience Co Ltd filed Critical Idience Co Ltd
Publication of MX2022013304A publication Critical patent/MX2022013304A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

La presente memoria descriptiva proporciona formas cristalinas de clorhidrato de 4-[3-(3- [(ciclopropilamino)metil]azetidin-1-carbon il)-4-fluorobencil]ftalazin-1(2H)-ona, métodos para prepararlas y composiciones farmacéuticas que las comprenden.
MX2022013304A 2020-04-21 2020-04-24 Formas cristalinas de compuesto de ftalazinona. MX2022013304A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063013276P 2020-04-21 2020-04-21
PCT/IB2020/000324 WO2021214503A1 (en) 2020-04-21 2020-04-24 Crystalline forms of phthacaz1nonf compound

Publications (1)

Publication Number Publication Date
MX2022013304A true MX2022013304A (es) 2022-12-15

Family

ID=78081129

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022013304A MX2022013304A (es) 2020-04-21 2020-04-24 Formas cristalinas de compuesto de ftalazinona.

Country Status (13)

Country Link
US (2) US11390608B2 (es)
EP (1) EP4139297A4 (es)
JP (1) JP2023537550A (es)
KR (1) KR20230004723A (es)
CN (1) CN115702151A (es)
AR (1) AR121289A1 (es)
AU (1) AU2020444056A1 (es)
BR (1) BR112022021321A2 (es)
CA (1) CA3176219A1 (es)
IL (1) IL297464A (es)
MX (1) MX2022013304A (es)
TW (1) TW202140456A (es)
WO (1) WO2021214503A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023144626A1 (en) * 2022-01-25 2023-08-03 Idience Co., Ltd. Pharmaceutical composition including phthalazinone derivative for co-administration with anticancer drug

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1330442B1 (en) 2000-10-30 2011-01-19 Kudos Pharmaceuticals Limited Phthalazinone derivatives
US6627646B2 (en) * 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs
ATE491703T1 (de) 2002-04-30 2011-01-15 Kudos Pharm Ltd Phthalazinonderivate
PL1633724T3 (pl) 2003-03-12 2011-10-31 Kudos Pharm Ltd Pochodne ftalazynonu
US7449464B2 (en) 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
JP5271897B2 (ja) 2006-05-31 2013-08-21 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・エルレ・エルレ ポリ（ＡＤＰ−リボース）ポリメラーゼ（ＰＡＲＰ）の阻害剤としての、ピロロ［１，２−ａ］ピラジン−１（２Ｈ）−オン及びピロロ［１，２−ｄ］［１，２，４］トリアジン−１（２Ｈ）−オン誘導体
GB0610680D0 (en) 2006-05-31 2006-07-12 Istituto Di Ricerche D Biolog Therapeutic compounds
CN103690542B (zh) 2006-12-28 2015-11-18 Abbvie公司 聚(adp-核糖)聚合酶抑制剂
AU2008322676B9 (en) 2007-11-15 2014-03-27 Msd Italia S.R.L. Pyridazinone derivatives as PARP inhibitors
UY31603A1 (es) 2008-01-23 2009-08-31 Derivados de ftalazinona
GB0804755D0 (en) 2008-03-14 2008-04-16 Angeletti P Ist Richerche Bio Therapeutic compounds
EP2598491B1 (en) 2010-07-27 2015-09-02 Cadila Healthcare Limited Substituted 4-(4-fluoro-3-(piperazine-1- carbonyl)benzyl)phthalazin-1(2h)-one derivatives as poly (adp-ribose) polymerase- 1 inhibitors
CN102372716A (zh) 2010-08-09 2012-03-14 江苏恒瑞医药股份有限公司 酞嗪酮类衍生物、其制备方法及其在医药上的应用
CN102372706A (zh) 2010-08-09 2012-03-14 江苏恒瑞医药股份有限公司 酞嗪酮类衍生物、其制备方法及其在医药上的应用
CN102372698A (zh) 2010-08-10 2012-03-14 江苏恒瑞医药股份有限公司 酞嗪酮类衍生物、其制备方法及其在医药上的应用
US8999985B2 (en) 2010-12-02 2015-04-07 Shanghai De Novo Pharmatech Co Ltd. Substituted phthalazin-1(2H)-ones, preparation processes and medical uses thereof
CN102485721B (zh) 2010-12-03 2015-12-09 曹亚 取代的2,3-二氮杂萘酮化合物及其用途
CN103130723B (zh) 2011-11-30 2015-01-14 成都地奥制药集团有限公司 一种多聚(adp-核糖)聚合酶抑制剂
KR101670126B1 (ko) * 2013-09-13 2016-10-27 일동제약(주) 신규 프탈라지논 유도체 및 그 제조방법
KR20170037116A (ko) 2015-09-25 2017-04-04 일동제약(주) 플루오로기가 치환된 프탈라지논 유도체 및 그 제조방법
WO2017191650A1 (en) 2016-05-03 2017-11-09 Msn Laboratories Private Limited Process for the preparation of 5-[[[(2s)-2-amino-3-[4-(aminocarbonyl)-2,6-dimethylphenyl]-1-oxopropyl][(1s)-1-(4-phenyl-1h-imidazol-2-yl)ethyl]amino]methyl-2-methoxybenzoic acid and its polymorphs thereof

Also Published As

Publication number Publication date
KR20230004723A (ko) 2023-01-06
TW202140456A (zh) 2021-11-01
US11691964B2 (en) 2023-07-04
AR121289A1 (es) 2022-05-04
CA3176219A1 (en) 2021-10-28
US20210323945A1 (en) 2021-10-21
JP2023537550A (ja) 2023-09-04
WO2021214503A1 (en) 2021-10-28
AU2020444056A1 (en) 2022-11-17
BR112022021321A2 (pt) 2022-12-20
EP4139297A4 (en) 2024-05-22
US20220372020A1 (en) 2022-11-24
CN115702151A (zh) 2023-02-14
EP4139297A1 (en) 2023-03-01
IL297464A (en) 2022-12-01
US11390608B2 (en) 2022-07-19

Similar Documents

Publication Publication Date Title
AU2021323253A8 (en) Heterocyclic GLP-1 agonists
HRP20080446T3 (en) Monohydrochloride salt of 1-[3-[3-(4-chlorophenyl)propoxy]propyl]-piperidine
MX2021000309A (es) Derivados de 3-(5-hidroxi-1-oxoisoindolin-2-il)piperidina-2,6-dion a y su uso en el tratamiento de enfermedades dependientes del dedo de zinc 2 de la familia ikaros (ikzf2).
RS53196B (en) INHIBITORI POLI (ADP-RIBOZA) POLIMERAZE
NO20063599L (no) Ytterligere heterosykliske forbindelser og deres anvendelse som metabotrofiske glutamatreseptorantagonister
MX2021009764A (es) Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona sustituidos y usos de los mismos.
RU2437882C2 (ru) Производные имидазолидинона
MX2022009524A (es) Agonistas heterociclicos de glp-1.
EA200901514A1 (ru) Новая сольватная и кристаллическая форма производных карбамоилциклогексана
MX2021007473A (es) Compuestos de 3-((3-aminofenil)amino)piperidina-2,6-diona sustituida, composiciones de estos y metodos de tratamiento con estos.
NO20064366L (no) Tiazolderivat
NO20092286L (no) Nitrogenhaldige heterosykliske forbindelser og anvendelse derav
TNSN07279A1 (en) Pyrazole derivatives for the inhibition of cdk's and gsk's
UA90757C2 (ru) Гербицидная композиция, способ борьбы с нежелательной растительностью и способ защиты посевов от фитотоксичного действия 3-фенилурацилов
NO20062726L (no) Nye pyridazin-3(2H)-on derivater
HUP0301336A2 (hu) Réztartalmú amin-oxidázok inhibitorai és alkalmazásuk gyógyszerkészítmények előállítására
SI1651040T1 (sl) Fungicidne kombinacije ternarnih aktivnih snovi
DK1539734T3 (da) Quinolylpropylpiperidinderivater og deres anvendelse som antimikrobielle midler
MX2022013304A (es) Formas cristalinas de compuesto de ftalazinona.
DE602004009200D1 (de) Tetrahydrochinazolinderivate als cfr-antagonisten
MX2021010133A (es) Forma cristalina de 1-(1-oxo-1,2-dihidroisoquinolin-5-il)-5-(trifl uorometil)-n-(2-(trifluorometil)piridin-4-il)-1h-pirazol-4-carbox amida monohidratada.
MX2021007475A (es) Compuestos de 3-((3-aminofenil)amino)piperidina-2,6-diona sustituida, composiciones de estos y metodos de tratamiento con estos.
MX2021003083A (es) Formas cristalinas de un agonista del receptor de farnesoide x.
MY157375A (en) Novel crystalline forms of <2-[1-(3,5-bis-trifluoromethyl-benzyl)-5-pyridin-4-yl-1h-[1,2,3]triazol-4-yl]-pyridin-3-yl>-(2-chlorophenyl)-methanone
PH12021550456A1 (en) Crystalline forms of a quinazole compound and its hydrochloride salts